Drug Type CIR-NK |
Synonyms Anti-HLA-G(NKILT), NKL 001, NKL001 |
Target |
Action inhibitors |
Mechanism HLA-G inhibitors(major histocompatibility complex, class I, G inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Preclinical | United States | 28 Apr 2025 | |
Acute Myeloid Leukemia | Preclinical | United States | 03 Nov 2023 |